|Bid||86.36 x 800|
|Ask||86.94 x 1100|
|Day's Range||85.78 - 86.71|
|52 Week Range||65.44 - 88.76|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||46.93|
|Earnings Date||Jan 21, 2020 - Jan 27, 2020|
|Forward Dividend & Yield||1.28 (1.49%)|
|1y Target Est||94.03|
Zoetis, which develops products for pets and livestock, plans to increase its quarterly dividend 22% to 20 cents a share. Franklin Resources, Abbott Laboratories, and Amgen are among the other companies boosting dividends.
Abbott Laboratories said Friday its board has approved a 12.5% increase in its quarterly dividend to 36 cents a share. The new dividend will be payable Feb. 14 to shareholders of record as of Jan. 15. Abbott shares were slightly higher Friday, but have gained 19% in 2019, while the S&P 500 has gained 26%.
The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 36 cents per share – a 12.5% increase.
Aung San Suu Kyi has launched a trenchant defence of Myanmar against genocide allegations, insisting that accusers were painting an “incomplete and misleading” picture of a military crackdown that triggered an exodus of Rohingya Muslims. The Myanmar leader — who once won worldwide acclaim for her resistance to the country’s former junta — rejected allegations made by the African nation of Gambia that military “clearance operations” starting in 2016 amounted to genocidal acts.
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2, is it time to buy Abbott stock?
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Today we'll take a closer look at Abbott Laboratories (NYSE:ABT) from a dividend investor's perspective. Owning a...
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
At Insider Monkey, we pore over the filings of around 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this article, […]
Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.
During Wednesday's Mad Money program, Jim Cramer told his viewers to never bet against a great brand and CEO. This is true of Abbott Laboratories under the outgoing Miles White. This is a company you can trust, Cramer concluded, and they should be bought on any weakness.
Abbott Laboratories announced Wednesday that Chief Operating Officer Robert Ford would succeed Chief Executive Miles White in March. Abbott stock dipped a fraction at the close.
After nearly 21 years at Abbott Laboratories (NYSE: ABT ), CEO Miles White is preparing for his departure. The company announced Wednesday that White will leave March 31 and be replaced by Robert Ford, ...
After leading the company for 21 years, Abbott Laboratories CEO Miles White will step down next year. White, 64, will leave the Abbott Park healthcare giant (NYSE: ABT) on March 31, and will be replaced by Robert Ford, 46, the company's current chief operating officer and president. Ford will become the 13th CEO of Abbott in its 131-year history, the company said, adding that White's tenure is the second longest for a non-founder in today's S&P 100.
Miles White, who has led the business since 1999, will be succeeded by Robert Ford, president and chief operating officer of the pharmaceutical and medical-devices company.
Abbott Laboratories longtime Chief Executive Officer Miles White will step down in favor of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals. White, 64, will remain the executive chairman and will be succeeded by Chief Operating Officer Robert Ford, who he appointed last year as part of succession planning. Abbott's shares have gained more than four-fold during White's more than two decades at the helm.
Abbott Laboratories said Wednesday that Chief Executive Miles White will step down on March 31, 2020, after 21 years in the role. White, who joined Abbott in 1984, will remain executive chairman. The healthcare company said Robert Ford, who has been chief operating officer since October 2018 and a 23-year Abbott veteran, will succeed White as CEO. Abbott's stock slipped 0.3% in premarket trading. It has rallied 21.4% over the past 12 months through Tuesday, while the SPDR Health Care Select Sector ETF has gained 4.7% and the S&P 500 has advanced 13.6%.